Therapeutics News and Research

RSS

Pain control in osteoarthritis patients

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.

9 Jul 2014

Scientists release recommendations for evaluating pharmacological safety of oligonucleotide therapeutics

Novel oligonucleotide-based drugs in development offer promising alternatives for treating a range of diseases.

8 Jul 2014

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of hepatocellular carcinoma (HCC).

7 Jul 2014

genOway to provide EUCOMM conditional knockout mouse models to study human diseases

genOway, the biotechnology company dedicated to the development of genetically modified animal models, the Wellcome Trust Sanger Institute (UK) and Helmholtz Zentrum München (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS (EUCOMM: Tools for functional annotation of the mouse genome) announce today the signing of a license enabling genOway to provide industry scientists with conditional knockout (KO) models developed by EUCOMM.

3 Jul 2014

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

Akashi Therapeutics, Inc., announced today that the U.S. Food and Drug Administration has granted Fast Track designation to the company's most advanced product candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD.

3 Jul 2014

Analysis of clinical trials reveals urgent need to increase Alzheimer's drug development

Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments.

3 Jul 2014

MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections

AIMM Therapeutics, a leading human therapeutic antibody company, today announced that its partner MedImmune, LLC, the global biologics unit of AstraZeneca, has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children.

2 Jul 2014

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK), one of the most common types of skin tumors.

1 Jul 2014

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Therapeutics, LLC, today announced that the Company has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex® Sprinkle™ (rabeprazole sodium), Delayed-Release Capsules, 5 mg and 10 mg, for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks.

30 Jun 2014

Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.

30 Jun 2014

Complete analysis of regenerative medicine market

According to a new market research report by Allied Market Research titled, "GlobalRegenerative MedicineMarket (Technology, Applications, Geography) - Industry Analysis, Trends, Opportunities and Forecast, 2013-2020", the global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020).

30 Jun 2014

Affimed Therapeutics files Form F-1 registration statement for public offering of common stock

Affimed Therapeutics today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares.

30 Jun 2014

Lassa virus uses two-step process to invade cells, shows study

Scientists have discovered that the Lassa virus, which is endemic to West Africa, uses an unexpected two-step process to enter cells.

28 Jun 2014

Researchers identify microorganisms that may trigger diarrheal disease among children

In a finding that may one day help control a major cause of death among children in developing countries, a team of researchers led by faculty from the University of Maryland, College Park and the University of Maryland School of Medicine has identified microorganisms that may trigger diarrheal disease and others that may protect against it.

28 Jun 2014

USAMRIID scientists propose new standards to sequence viral genomes

Scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have proposed a set of standards aimed at developing a common "language" among investigators working to sequence viral genomes and characterize viral stocks.

26 Jun 2014

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.

25 Jun 2014

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors.

24 Jun 2014

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana Therapeutics, Inc., and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs).

24 Jun 2014

Researchers develop GI microbiome modulators to treat prediabetes and diabetes

In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal (GI) tract improves glucose tolerance-the body's response to consuming carbohydrates- after four weeks of treatment and without a change in diet.

24 Jun 2014

Complementary medicines: an interview with Associate Professor Evelin Tiralongo, Griffith University

Complementary medicines are generally being defined as medicines which are non-mainstream medicines and are mostly given together with conventional medicines.

23 Jun 2014

Therapeutics News and Research

Pain control in osteoarthritis patients

Scientists release recommendations for evaluating pharmacological safety of oligonucleotide therapeutics

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

genOway to provide EUCOMM conditional knockout mouse models to study human diseases

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

Analysis of clinical trials reveals urgent need to increase Alzheimer's drug development

MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

Complete analysis of regenerative medicine market

Affimed Therapeutics files Form F-1 registration statement for public offering of common stock

Lassa virus uses two-step process to invade cells, shows study

Researchers identify microorganisms that may trigger diarrheal disease among children

USAMRIID scientists propose new standards to sequence viral genomes

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Researchers develop GI microbiome modulators to treat prediabetes and diabetes

Complementary medicines: an interview with Associate Professor Evelin Tiralongo, Griffith University

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News